Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines

Abstract

BackgroundAlthough metastasis is ultimately responsible for about 90% of breast cancer mortality, the vast majority of breast-cancer-related deaths are due to progressive recurrences from non-metastatic disease. Current adjuvant therapies are unable to prevent progressive recurrences for a significant fraction of patients with breast cancer. Autologous tumor cell vaccines (ATCVs) are a safe and potentially useful strategy to prevent breast cancer recurrence, in a personalized and patient-specific manner, following standard-of-care tumor resection. Given the high intra-patient and inter-patient heterogeneity in breast cancer, it is important to understand which factors influence the immunogenicity of breast tumor cells in order to maximize ATCV effectiveness.MethodsThe relative immunogenicity of two murine breast carcinomas, 4T1 and EMT6, were compared in a prophylactic vaccination-tumor challenge model. Differences in cell surface expression of antigen-presentation-related and costimulatory molecules were compared along with immunosuppressive cytokine production. CRISPR/Cas9 technology was used to modulate tumor-derived cytokine secretion. The impacts of cytokine deletion on splenomegaly, myeloid-derived suppressor cell (MDSC) accumulation and ATCV immunogenicity were assessed.ResultsMice vaccinated with an EMT6 vaccine exhibited significantly greater protective immunity than mice vaccinated with a 4T1 vaccine. Hybrid vaccination studies revealed that the 4T1 vaccination induced both local and systemic immune impairments. Although there were significant differences between EMT6 and 4T1 in the expression of costimulatory molecules, major disparities in the secretion of immunosuppressive cytokines likely accounts for differences in immunogenicity between the cell lines. Ablation of one cytokine in particular, granulocyte-colony stimulating factor (G-CSF), reversed MDSC accumulation and splenomegaly in the 4T1 model. Furthermore, G-CSF inhibition enhanced the immunogenicity of a 4T1-based vaccine to the extent that all vaccinated mice developed complete protective immunity.ConclusionsBreast cancer cells that express high levels of G-CSF have the potential to diminish or abrogate the efficacy of breast cancer ATCVs. Fortunately, this study demonstrates that genetic ablation of immunosuppressive cytokines, such as G-CSF, can enhance the immunogenicity of breast cancer cell-based vaccines. Strategies that combine inhibition of immunosuppressive factors with immune stimulatory co-formulations already under development may help ATCVs reach their full potential.Electronic supplementary materialThe online version of this article (10.1186/s13058-018-1054-3) contains supplementary material, which is available to authorized users.

Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer

“…It is conceivable that such tumor-derived signals are able to program myeloid cells towards an tumor-promoting phenotype, with systemic effects targeting spleen and bone marrow. A crucial factor involved in the generation and pathological activation of PMN-MDSC is the growth factor G-CSF, and systemic levels of G-CSF have been correlated with MDSC accumulation in several tumor models [46, 51, 52]. We speculate that G-CSF also accounts for the pathological activation of PMN-MDSC in KPC-derived pancreatic cancer, as elevated G-CSF serum levels during tumor progression correlated with the frequency of PMN-MDSC in spleen and blood.…”

Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy

“…These findings are essentially in agreement with several earlier experimental studies in murine models of experimental colon cancer and NSCLC, in which neutrophilic inflammation resulting from tumor expression of the neutrophil-recruiting cytokine IL-17A was associated with disease progression and decreased responsiveness to PD-1-targeted immunotherapy [39,40]. In a somewhat similar context, another recent experimental animal study revealed that production of G-CSF by murine breast carcinomas was associated with attenuation of the therapeutic activity of breast tumor-targeted vaccines [41].…”

Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression

“…To examine whether MPLAs provokes the production of immunosuppressive cytokines, we collected the conditioned media from MPLAs-treated A375 cells and conducted a cytokine array assay. Results showed that several immunosuppressive cytokines, including ICAM-1 21 , IL-6 22 , CXCL12 22 , G-CSF 23 , and PAI-1 24 , were increased upon MPLAs stimulation (Fig. 3e, f).…”